1795736-60-5

1795736-60-5 structure

Name: BCR-ABL-IN-5
Chemical Name: BCR-ABL-IN-5
CAS Number: 1795736-60-5
Molecular Formula: C₂₅H₂₁Cl₂N₅O₂
Molecular Weight: 494.37
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK Bcr-Abl
Create Date: 2022-08-31 19:22:35
Modify Date: 2024-01-09 16:33:18
BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-AblWT and Bcr-AblT3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells[1].

Name	BCR-ABL-IN-5

Description	BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-AblWT and Bcr-AblT3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Bcr-Abl
Target	IC50: 6.5 μM (K562)[1].
In Vitro	BCR-ABL-IN-5 (compound II) (0-100 mM, 72 hours) can inhibit the proliferation of K562 human leukemia cells[1]. Cell Proliferation Assay[1] Cell Line: K562 human leukemia cell line Concentration: 0-100 μM Incubation Time: 72 hours Result: Inhibited K562 proliferation with an IC50 value of 6.5 μM.
References	[1]. Ashraf K El-Damasy, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. Eur J Med Chem. 2020 Dec 1;207:112710.

Molecular Formula	C₂₅H₂₁Cl₂N₅O₂
Molecular Weight	494.37